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Abstract
Fibrocytes, a group of bone marrow-derived mesenchymal progenitor cells, were first described in 1994 as
fibroblast-like, peripheral blood cells that migrate to regions of tissue injury. These cells are unique in their
expression of extracellular matrix proteins concomitantly with markers of hematopoietic and monocyte lineage.
The involvement of fibrocytes and the specific role they play in the process of wound repair has been a focus of
study since their initial description. Fibrocytes contribute to the healing repertoire via several mechanisms; they
produce a combination of cytokines, chemokines, and growth factors to create a milieu favorable for repair to
occur; they serve as antigen presenting cells (APCs); they contribute to wound closure; and, they promote
angiogenesis. Furthermore, regulatory pathways involving serum amyloid P, leukocyte-specific protein 1, and
adenosine A2A receptors have emphasized the significant role that fibrocytes have in wound healing and fibrosis.
The therapeutic targeting of fibrocytes holds promise for the augmentation of wound repair and the treatment of
different fibrosing disorders.
The first study of fibrocytes was performed in a murine
model of wound repair, which relied on surgical implanta-
tion of wound chambers in subcutaneous tissues. Subse-
quent examination of peripheral blood cells within two
days of wound chamber implantation revealed a fibro-
blast-like circulating CD34
+ and Col I
+ cell that was in the
exudate fluid–adherent and spindle-shaped–and thus
termed a fibrocyte [1].
Since their original description, the wealth of informa-
tion regarding fibrocyte biology has grown steadily and
implicated this cell in wound healing and in many disease
states that can be regarded as aberrant wound healing,
including hypertrophic scars and keloids, airway remodel-
ing in asthma, interstitial pulmonary fibroses, systemic
fibroses, atherosclerosis, and the stromal response to
tumor invasion [2,3].
Phenotypic examination of these cells reveals a unique
cytokine and chemokine profile distinct from mono-
cytes, dendritic cells, Langerhans cells, T lymphocytes,
fibroblasts, endothelial cells, and epithelial cells. Fibro-
cytes express fibroblast components such as vimentin,
collagen I, collagen III, and fibronectin, and they express
the hematopoietic stem cell marker (CD34) and the leu-
kocyte common antigen (CD45) [1]. Moreover, fibro-
cytes exhibit unique cytoplasmic extensions that are
intermediate in size between microvilli and pseudopodia
[1]. Fibrocytes comprise approximately 0.5% of non-
erythrocytic cells in the peripheral blood, and they dif-
ferentiate from CD14+ cells in culture into a phenotype
with wound healing potential.
Initial observations of their recruitment to wound sites
were found to be due to specific chemokine-chemokine
receptor interactions. Namely, it was shown that fibrocytes
migrate to wounds in response to secondary lymphoid
chemokine (SLC), which is the ligand for CCR7 [4]. The
fibrocyte chemokine expression profile also has revealed
other chemokine receptors on the surface of fibrocytes,
such as CCR3, CCR5, CCR7, and CXCR4 [4], which also
likely function in fibrocyte signaling and trafficking
pathways.
Fibrocytes produce a combination of cytokines, chemo-
kines, and growth factors that create a milieu favorable
for repair. In cutaneous wounds, the CD34 hematopoietic
marker initially expressed by fibrocytes decreases over
time. This decrease in CD34 occurs in concert with the
increased expression of prolyl-4-hydroxylase, an enzyme
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helix [5]. It is hypothesized that CD34 expression reflects
the inflammatory state of the wound, which is down
regulated as fibrocytes differentiate into a more mature
connective tissue cell [5]. The leukocyte common antigen
(CD45) displays a similar decrease in expression as fibro-
cytes differentiate [6]. This phenotypic transition of fibro-
cytes is also evident in the context of an increase in
expression of TGF-b1 in the wound [5]. TGF-b1, a cyto-
kine that plays an important role in tissue repair and
fibrosis, was found to accelerate fibrocyte differentiation
to cells that are phentoypically similar to mature fibro-
blasts and myofibroblasts, in vitro [4]. Furthermore,
fibrocytes were found to be an important source of cyto-
kines and type I collagen during the inflammatory and
repair phase of wound healing. High levels of IL-1b were
observed to induce the fibrocyte secretion of chemokines
(MIP-1a, MIP-1b), fibrogenic cytokines including TNFa,
and hematopoietic growth factors (M-CSF, IL-6, IL-10)
[7].
Fibrocytes are potent antigen presenting cells that are
capable of initiating and promoting T cell immunity. They
constitutively express surface proteins required for antigen
presentation including class II major histocompatability
complex molecules (HLA-DP, HLA-DQ, and HLA-DR)
and the costimulatory molecules CD80 and CD86 [8]. In
addition, fibrocytes express the adhesion molecules
CD11a, CD54 and CD58 [8]. Furthermore, human fibro-
cytes were found to induce a tetanus-toxoid specific T cell
response that was greater than that induced by peripheral
blood monocytes and equivalent to that produced by den-
dritic cells [8]. In confirmation of in vitro studies, in vivo
studies showed that mouse fibrocytes pulsed with foreign
antigen and injected in skin migrate to regional lymph
nodes and prime naïve T cells [8]. Fibrocytes, therefore,
exhibit a potent antigen presenting capability, indicating
their likely role in the initiation of immunity during injury,
wound repair, and in fibrotic responses associated with
inflammation, such as granulomas and scleroderma.
Wound closure is an essential part of wound healing, in
which myofibroblasts play an active role. Fibrocytes have
been shown to express alpha smooth muscle actin
(aSMA) and contract collagen gels in vitro, revealing their
potential to differentiate into myofibroblasts and contri-
bute to wound contraction [4]. Indeed, fibrocytes also
were found to differentiate to a myofibroblast phenotype
in vivo and express aSMA, thereby confirming that these
circulating cells contribute to a subset of myofibroblasts in
wounds and are integral mediators of wound healing [6].
Fibrocytes have been shown to promote angiogenesis,
which is a requisite for the development and mainte-
nance of new granulation tissue, allowing wound closure
and restoration of tissue integrity. Cultured fibrocytes
participate in all aspects of neovascularization. They are
involved in the proteolysis of the basement membrane by
constitutively secreting extracellular matrix degrading
enzymes, namely matrix metalloproteinase 9 (MMP-9),
thus allowing for endothelial cell invasion. Fibrocytes are
involved in the proliferation, migration and tube forma-
tion of endothelial cells in vitro by their secretion of vas-
cular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), IL-8, platelet derived growth factor
(PDGF), and hematopoietic growth factors. Moreover,
these results were supported by in vivo studies using the
Matrigel implant model, where the introduction of fibro-
cytes promoted the formation of new blood vessels [9].
The pro-angiogenic properties of fibrocytes are clearly
vital for wound repair, and these findings may provide
therapeutic opportunities in the promotion of wound
repair.
In order to determine whether these unique cells,
indeed, had their origins in the bone marrow, experimen-
tal murine models of sex-mismatched bone marrow chi-
mera mice were utilized. In this model, female mice, after
total body irradiation, received a male whole bone marrow
transplant. Further analysis by in situ hybridization of the
wounded tissue in these mice, revealed that circulating
fibrocytes and fibrocytes isolated from the wounded tissue
were male cells from the transplanted donor bone mar-
row, thus solidifying their hematopoietic origin [6]. In
another model, bone marrow from enhanced green fluor-
escent protein (EGFP) transgenic mice was transplanted
into normal mice. The injured skin of this murine model
was found to contain numerous EGFP+, bone-marrow-
derived cells. Most of these EGFP+ cells expressed CD45
and were phenotypically similar to fibrocytes, further
creating a case for the hematopoietic, stem cell origin of
fibrocytes [10].
The regulation of fibrocytes is a dynamic process gov-
erned by many factors, each harboring their own thera-
peutic potential. The profibrotic cytokines, IL-4 and IL-13,
along with platelet-derived growth factor (PDGF) promote
the differentiation of CD14+ precursors to fibrocytes [11].
Furthermore, the pro-inflammatory cytokines IL-12 and
IFN-g, along with serum amyloid P, and aggregated IgG
inhibit the maturation of CD14+ precursors into fibrocytes
[11-13]. The subsequent differentiation of fibrocytes to
mature mesenchymal cells is stimulated with TGF-b1, as
stated previously, as well as with endothelin-1 (ET-1), a
peptide that plays an important role in vascular homeosta-
tis [14]. Moreover, fibrocytes can diferentiate into adipo-
cytes when cultured in adipogenic conditions [15],
indicating the potential of this cell to differentiate into
more than one mesenchemyal cell type.
Recent studies implicating leukocyte-specific protein 1
(LSP1), adenosine A2A receptors, and serum amyloid P
(SAP) in fibrocyte regulation have further elucidated the
role that fibrocytes play, specifically, in the process of
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peutic potential.
LSP1, a cytoskeletal protein reported to be important for
leukocyte chemotaxis, may also play a regulatory role in
wound healing and fibrocyte biology. Both leukocytes and
fibrocytes express LSP1, however fibroblasts do not. More-
over, LSP1 expression persists in fibrocytes and is more
u p r e g u l a t e di nf i b r o c y t e st h a ni ti si nl e u k o c y t e s[ 1 6 ] .
Interestingly, LSP1
-/- null mice show accelerated healing
of skin wounds, along with enhanced collagen synthesis,
re-epithelialization, and angiogenesis. Furthermore, the
number of fibrocytes in these mice is substantially higher
than in wild type mice; and thus, the accelerated wound
healing observed in LSP1
-/- mice could, partly, be asso-
ciated with elevated fibrocyte levels [17]. In using this
same mouse model and injecting bleomcyin to induce a
fibrotic response, the numbers of fibrocytes in LSP1 defi-
cient mice were increased in comparison to WT. Fibro-
cytes therefore, are not only implicated in the increased
fibrosis that is noticed with these mice, but they also are
likely a result of an increased mononuclear infiltrate [18].
Thus, elevated fibrocyte levels may accelerate wound heal-
ing as well as contribute to pathologic fibrosis.
Adenosine has long been associated with a role in the
inflammatory response, which is important for wound
healing. It has been shown that adenosine A2 receptor
agonists play a beneficial role in wound healing in normal
and diabetic animals [19]. Recently, it has become evident
that adenosine A2A receptors may function in the prolif-
eration and differentiation of mouse bone marrow-derived
mesenchymal stem cells (BM-MSCs) [20]. Consistent with
these results, the deletion or the blockade of adenosine
A2A receptors results in less fibrocyte accumulation in the
dermis of a bleomycin-treated murine model of sclero-
derma. Fibrocyte accumulation, therefore, is somehow
regulated by adenosine A2A receptors [21]. Whether fibro-
cytes are directly recruited by adenosine A2A receptors to
tissue, or whether the adenosine A2A receptors stimulate
the differentiation of precursors to fibrocytes, remains to
be further studied. However, the implication that adeno-
sine A2A receptors may represent a therapeutic target for
treating fibrosing diseases is an exciting one.
SAP, which is a member of the pentraxin family of pro-
teins, is a critical factor in plasma that inhibits fibrocyte
differentiation from monocytes ex vivo [12]. In a recent
study, it has been shown that the administration of exo-
genous SAP, either locally or systemically, compromises
dermal wound healing [22]. SAP-treated wounds showed a
decreased rate of wound closure and a decreased number
of myofibroblasts at 7 days postwounding [22]. These
results are most likely a consequence of an inhibition of
fibrocyte differentiation into myofibroblasts. SAP, there-
fore, represents a potential tool to either ameliorate the
efficiency of normal wound healing or prevent aberrant
wound healing processes through their regulation of
fibrocytes.
In general, adult wound healing results in scar formation,
typified by a dysregulated reconstitution of the collagen
matrix. Hypertrophic scars represent one form of an aber-
rant and exuberant wound healing process. Fibrocytes
were detected in greater numbers in postburn hyper-
trophic scar tissue as compared to mature scar tissue and
normal dermis, therefore fortifying the hypothesis that
they are involved in the development and perpetuation of
aberrant wound healing [16]. It has been shown that fibro-
cytes from either burn patients or normal patients have a
much lower ability to synthesize collagen in vitro than do
dermal fibroblasts. This finding raises the possibility that
the primary role of fibrocytes in the healing of burn
wounds may not be in deposition of ECM, and may instead
be by the regulation of dermal fibroblasts [23]. Dermal
fibroblasts, when conditioned with medium from burn
patient fibrocytes, possess a heightened ability to prolifer-
ate and migrate, to express aSMA, and to contract col-
lagen lattices in vitro [23]. Furthermore, the profibrotic
factors, TGF-b1 and CTGF (connective tissue growth fac-
tor), are produced in greater quantities by the fibrocytes of
burn patients, and these cytokines may be integral regula-
tors of fibroblast activity in response to thermal injury [23].
Thus, as indicated by this example, the regulation of fibro-
cytes in pathologic contexts, also awaits further refinement.
Since their first description in 1994, the biology of fibro-
cytes has been expanded considerably. In wound repair,
they have been shown to produce a combination of cyto-
kines, chemokines, and growth factors necessary for the
healing process. In addition, their role in antigen presenta-
tion, wound closure, and angiogenesis has been demar-
cated. Fibrocyte regulation via LSP1, adenosine A2A
receptors, and SAP has also been shown and awaits
further characterization. In general, a more detailed view
of how fibrocytes mobilize and the trafficking signals they
require, as well as how they differentiate, must be further
elucidated. There is currently no FDA-approved therapy
for fibrosing diseases, and so, a better understanding of
fibrocytes and their regulation marks these bone marrow-
derived progenitors as potential therapeutic modalities to
not only augment normal wound healing, but also poten-
tially reverse fibrosis in many disease states.
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